SK279759B6 - Použitie riluzolu na prípravu liečiva na liečenie - Google Patents

Použitie riluzolu na prípravu liečiva na liečenie Download PDF

Info

Publication number
SK279759B6
SK279759B6 SK786-95A SK78695A SK279759B6 SK 279759 B6 SK279759 B6 SK 279759B6 SK 78695 A SK78695 A SK 78695A SK 279759 B6 SK279759 B6 SK 279759B6
Authority
SK
Slovakia
Prior art keywords
treatment
riluzole
preparation
medicaments
injuries
Prior art date
Application number
SK786-95A
Other languages
English (en)
Slovak (sk)
Other versions
SK78695A3 (en
Inventor
Adam Doble
Erik Louvel
J�R�My Pratt
Jean-Marie Stutzmann
Original Assignee
Rhone-Poulenc Rorer S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone-Poulenc Rorer S.A. filed Critical Rhone-Poulenc Rorer S.A.
Publication of SK78695A3 publication Critical patent/SK78695A3/sk
Publication of SK279759B6 publication Critical patent/SK279759B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Data Exchanges In Wide-Area Networks (AREA)
SK786-95A 1992-12-16 1993-12-10 Použitie riluzolu na prípravu liečiva na liečenie SK279759B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9215148A FR2699077B1 (fr) 1992-12-16 1992-12-16 Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
PCT/FR1993/001229 WO1994013288A1 (fr) 1992-12-16 1993-12-10 Application du riluzole dans le traitement de lesions neurologiques liees a des traumatismes

Publications (2)

Publication Number Publication Date
SK78695A3 SK78695A3 (en) 1996-05-08
SK279759B6 true SK279759B6 (sk) 1999-03-12

Family

ID=9436652

Family Applications (3)

Application Number Title Priority Date Filing Date
SK786-95A SK279759B6 (sk) 1992-12-16 1993-12-10 Použitie riluzolu na prípravu liečiva na liečenie
SK787-95A SK78795A3 (en) 1992-12-16 1993-12-10 Application of lamotrigine in the treatment of neurological lesions related to traumatic injuries
SK785-95A SK78595A3 (en) 1992-12-16 1993-12-10 Anticonvulsive agents for treatment of neurological lesions

Family Applications After (2)

Application Number Title Priority Date Filing Date
SK787-95A SK78795A3 (en) 1992-12-16 1993-12-10 Application of lamotrigine in the treatment of neurological lesions related to traumatic injuries
SK785-95A SK78595A3 (en) 1992-12-16 1993-12-10 Anticonvulsive agents for treatment of neurological lesions

Country Status (23)

Country Link
US (1) US5830907A (no)
EP (3) EP0674512B1 (no)
JP (3) JPH08504429A (no)
KR (3) KR100298808B1 (no)
AT (1) ATE164067T1 (no)
AU (3) AU5653994A (no)
CA (3) CA2151604C (no)
CZ (3) CZ154695A3 (no)
DE (1) DE69317578T2 (no)
DK (1) DK0674512T3 (no)
ES (1) ES2113635T3 (no)
FR (1) FR2699077B1 (no)
GR (1) GR3026403T3 (no)
HU (3) HUT71839A (no)
IL (3) IL108052A0 (no)
MX (3) MX9307884A (no)
NO (3) NO307027B1 (no)
PL (3) PL309347A1 (no)
RU (1) RU2142800C1 (no)
SK (3) SK279759B6 (no)
UA (1) UA41906C2 (no)
WO (3) WO1994013298A1 (no)
ZA (3) ZA939400B (no)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
GB9424766D0 (en) * 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
FR2733684B1 (fr) 1995-05-03 1997-05-30 Cird Galderma Utilisation de retinoides dans une composition cosmetique ou pour la fabrication d'une composition pharmaceutique
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US20020022056A1 (en) 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
DE69816651T2 (de) 1997-09-05 2004-04-01 Glaxo Group Ltd., Greenford 2,3-diaryl-pyrazolo[1,5-b]pyridazin derivate, deren herstellung und deren verwendung als cyclooxygenase 2 (cox-2) inhibitoren
GB9808015D0 (en) * 1998-04-15 1998-06-17 United Medical And Dental Scho Protection of the nervous system from the effects of inflammatory disease
US6150423A (en) * 1998-10-15 2000-11-21 Phoenix Scientific, Inc. Propofol-based anesthetic and method of making same
FR2787028B1 (fr) * 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
EP1173175A1 (en) * 1999-04-29 2002-01-23 Centre National De La Recherche Scientifique (Cnrs) A method for the prevention of ischemic spinal cord injury caused by aortic crossclamping
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
GB9930058D0 (en) 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2007022568A1 (en) 2005-08-25 2007-03-01 Steven Michael Weiss Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
SG11201407300VA (en) 2012-05-07 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of neurological disorders
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
CN104603100A (zh) 2012-05-23 2015-05-06 塞利克斯比奥私人有限公司 用于治疗炎症性肠病的组合物和方法
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
US9765020B2 (en) 2012-05-23 2017-09-19 Cellix Bio Private Limited Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
WO2014037834A2 (en) 2012-09-08 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
CA2967908C (en) 2014-09-29 2020-11-17 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
EP3212626B1 (en) 2014-10-27 2018-11-07 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
SG11201705524SA (en) 2015-01-06 2017-08-30 Cellix Bio Private Ltd Compositions and methods for the treatment of inflammation and pain
AU2016328150B2 (en) 2015-09-23 2020-10-01 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
EP3601235A4 (en) * 2017-03-30 2020-11-18 XW Laboratories Inc. BICYCLIC HETERARYL DERIVATIVES, PREPARATION AND ASSOCIATED USES
US10322114B2 (en) 2017-07-31 2019-06-18 Above And Beyond Nb, Llc Formulation of a riluzole solution with beta-cyclodextrins
US20200289476A1 (en) * 2017-11-28 2020-09-17 University Of Houston System Liquid formulations of riluzole for oral and intravenous use
EP3856719B1 (en) 2018-09-30 2023-06-07 XWPharma Ltd. Compounds as neuronal histamine receptor-3 antagonists and uses thereof
CN115244028A (zh) 2019-12-20 2022-10-25 凯瑞康宁生物工程有限公司 4-缬氨酰氧基丁酸的合成方法
CN115803017A (zh) 2020-06-18 2023-03-14 凯瑞康宁生物工程有限公司 水溶性活性药物成分的药物造粒物
KR20230011359A (ko) 2020-06-18 2023-01-20 엑스더블유파마 리미티드 수용성 활성 약제 성분의 제어 방출 과립화물
CN116261451A (zh) 2020-07-24 2023-06-13 凯瑞康宁生物工程有限公司 γ-羟基丁酸衍生物的药物组合物和药物动力学
JP2023544420A (ja) 2020-10-05 2023-10-23 エックスダブリューファーマ リミテッド ガンマ－ヒドロキシ酪酸誘導体の調節放出組成物
JP2024511991A (ja) 2021-03-19 2024-03-18 エックスダブリューファーマ リミテッド ガンマ－ヒドロキシ酪酸誘導体の組み合わされた放出製剤の薬物動態

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0059987B1 (en) * 1979-06-01 1985-08-14 The Wellcome Foundation Limited Alpha-cyano-alpha-((n-guanidino)-imino) toluenes
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
US4826860A (en) * 1987-03-16 1989-05-02 Warner-Lambert Company Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
US4918090A (en) * 1988-01-25 1990-04-17 Warner-Lambert Company Substituted 2-aminbenzothiazoles and derivatives useful as cerebrovascular agents
US5240948A (en) * 1989-12-13 1993-08-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. 3-(3-alkylthiopropyl)benzothiazoline derivatives, their preparation and the medicament containing them
GB9012312D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
KR100246083B1 (ko) * 1991-02-08 2000-03-15 버틀러 그레고리 비. 신경전달물질의 방출조절물질인 치환 구아니딘류 및 그것의 유도체와 그들을 함유하는 약학 조성물
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.

Also Published As

Publication number Publication date
AU5654094A (en) 1994-07-04
AU5653994A (en) 1994-07-04
CZ154595A3 (en) 1995-11-15
DE69317578T2 (de) 1998-07-23
US5830907A (en) 1998-11-03
PL309348A1 (en) 1995-10-02
ZA939401B (en) 1994-08-19
JPH08504428A (ja) 1996-05-14
KR950703954A (ko) 1995-11-17
SK78595A3 (en) 1996-05-08
ZA939399B (en) 1994-08-22
JP3712239B2 (ja) 2005-11-02
PL309347A1 (en) 1995-10-02
KR950703965A (ko) 1995-11-17
HU217133B (hu) 1999-11-29
HU9501752D0 (en) 1995-08-28
ZA939400B (en) 1994-08-19
JPH08504429A (ja) 1996-05-14
NO307027B1 (no) 2000-01-31
CZ154695A3 (en) 1995-11-15
AU678795B2 (en) 1997-06-12
MX9307884A (es) 1994-06-30
CA2151601A1 (fr) 1994-06-23
HUT71814A (en) 1996-02-28
AU5702094A (en) 1994-07-04
GR3026403T3 (en) 1998-06-30
FR2699077A1 (fr) 1994-06-17
EP0674518A1 (fr) 1995-10-04
EP0674512A1 (fr) 1995-10-04
PL309346A1 (en) 1995-10-02
ES2113635T3 (es) 1998-05-01
HU9501753D0 (en) 1995-08-28
NO952230L (no) 1995-06-06
NO952228D0 (no) 1995-06-06
IL108051A (en) 1999-05-09
CA2151603A1 (fr) 1994-06-23
SK78795A3 (en) 1996-05-08
IL108051A0 (en) 1994-04-12
DK0674512T3 (da) 1998-05-25
FR2699077B1 (fr) 1995-01-13
CZ284420B6 (cs) 1998-11-11
ATE164067T1 (de) 1998-04-15
DE69317578D1 (de) 1998-04-23
HUT71812A (en) 1996-02-28
KR950703968A (ko) 1995-11-17
CA2151604C (fr) 2005-09-20
EP0674512B1 (fr) 1998-03-18
CA2151604A1 (fr) 1994-06-23
WO1994013288A1 (fr) 1994-06-23
MX9307882A (es) 1994-06-30
RU2142800C1 (ru) 1999-12-20
CZ154795A3 (en) 1995-11-15
IL108052A0 (en) 1994-04-12
NO952229D0 (no) 1995-06-06
WO1994013298A1 (fr) 1994-06-23
HU9501751D0 (en) 1995-08-28
IL108053A0 (en) 1994-04-12
UA41906C2 (uk) 2001-10-15
NO952228L (no) 1995-06-06
NO952230D0 (no) 1995-06-06
MX9307883A (es) 1994-06-30
SK78695A3 (en) 1996-05-08
WO1994013296A1 (fr) 1994-06-23
EP0674520A1 (fr) 1995-10-04
KR100298808B1 (ko) 2001-11-22
NO952229L (no) 1995-06-06
HUT71839A (en) 1996-02-28
JPH08504430A (ja) 1996-05-14

Similar Documents

Publication Publication Date Title
SK279759B6 (sk) Použitie riluzolu na prípravu liečiva na liečenie
SK279758B6 (sk) Parkinsonovejchoroby a parkinsonových syndrómov
US6284760B1 (en) Method of treating schizophrenia, depression and other neurological conditions
DE69635754T9 (de) Medikamente zur verhinderung von eingriffsbedingter stenose als folge von nicht-bypass invasiver eingriffe
DE10139410A1 (de) Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
DE3874229T2 (de) Verwendung von dioxopiperidin-derivaten zur herstellung eines topischen praeparates als analgetika.
Wang et al. Alkaloids of Chinese aconitum plants
EP0147185A2 (en) Therapeutic use of cytidyl disphosphocholine to increase neuronal acetylcholine
Koss et al. Potentiation of two sympathetic reflexes by yohimbine hydrochloride
EP1196170B1 (en) Use of a macrolide compound for the manufacture of a medicament for the treatment of brain damage caused by ischemia or hemorrhage
US5120739A (en) Method of treating motion sickness
FR2699078A1 (fr) Application de la lamotrigine dans le traitement de lésions neurologiques liées à des traumatismes.
FR2699079A1 (fr) Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20121210